Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- MeSH
- Lumbar Vertebrae physiopathology MeSH
- Biomarkers blood MeSH
- Phosphates blood MeSH
- Bone Density Conservation Agents administration & dosage therapeutic use MeSH
- Injections, Subcutaneous MeSH
- Isoenzymes blood MeSH
- Collagen Type I blood MeSH
- Bone Density drug effects MeSH
- Tartrate-Resistant Acid Phosphatase MeSH
- Acid Phosphatase blood MeSH
- Middle Aged MeSH
- Humans MeSH
- Peptide Fragments blood MeSH
- Peptides blood MeSH
- Osteoporosis, Postmenopausal blood drug therapy physiopathology MeSH
- Procollagen blood MeSH
- Drug Administration Schedule MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Teriparatide administration & dosage therapeutic use MeSH
- Calcium blood MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Randomized Controlled Trial MeSH
- Names of Substances
- Biomarkers MeSH
- collagen type I trimeric cross-linked peptide MeSH Browser
- Phosphates MeSH
- Bone Density Conservation Agents MeSH
- Isoenzymes MeSH
- Collagen Type I MeSH
- Tartrate-Resistant Acid Phosphatase MeSH
- Acid Phosphatase MeSH
- Peptide Fragments MeSH
- Peptides MeSH
- procollagen Type I N-terminal peptide MeSH Browser
- Procollagen MeSH
- Teriparatide MeSH
- Calcium MeSH
UNLABELLED: A 12-month morning teriparatide (TPTD) administration resulted in a larger increase in the lumbar spine bone mineral density (BMD) than the evening application. The results indicate that the response of bone cells to teriparatide treatment depends on dosing time. INTRODUCTION: The aim of this study was to assess the long-term effects of the morning vs. the evening teriparatide administration on BMD and bone turnover markers (BTMs) in postmenopausal osteoporosis. METHODS: Fifty women with established postmenopausal osteoporosis were randomized to 12-month treatment with 20 μg of TPTD, administered daily in the morning or in the evening. The BMD and serum concentrations of C-terminal telopeptide of type I collagen, N-terminal propeptide of type I procollagen (PINP), and tartrate-resistant acid phosphatase isoform 5b (TRAP 5b) were measured at baseline, after 6 and 12 months. General linear model-repeated measurements were used to analyze the data. RESULTS: After 12 months, the lumbar spine BMD grew markedly (p < 0.001) with a significantly greater increase in the morning arm compared to the evening arm (9.1% vs. 4.8%, respectively, p < 0.05). The BMD at the distal radius significantly decreased (p < 0.001), with no differences between the arms. The BMD at proximal femur did not change significantly. After 6 months, the BTMs were significantly increased compared with baseline (p < 0.001). The increases in the evening arm vs. the morning arm, however, were more pronounced in PINP (+358% vs. +215%, respectively) and in TRAP 5b (+70% vs. +37%, respectively) (both p < 0.05). CONCLUSION: 12-month morning administration of TPTD resulted in a larger increase in the lumbar spine BMD than the evening application. The timing of TPTD administration may be important for its efficacy.
See more in PubMed
J Bone Miner Res. 2005 Jun;20(6):962-70 PubMed
Osteoporos Int. 2011 Jun;22(6):1935-46 PubMed
Osteoporos Int. 1998;8(2):121-6 PubMed
J Clin Endocrinol Metab. 2005 Jul;90(7):3970-7 PubMed
N Engl J Med. 2003 Sep 25;349(13):1207-15 PubMed
J Clin Endocrinol Metab. 2010 Apr;95(4):1838-45 PubMed
Osteoporos Int. 2007 May;18(5):681-5 PubMed
Dan Med Bull. 1994 Apr;41(2):216-27 PubMed
J Bone Miner Res. 2007 Apr;22(4):495-502 PubMed
Metab Bone Dis Relat Res. 1982;4(1):1-6 PubMed
N Engl J Med. 2001 May 10;344(19):1434-41 PubMed
J Bone Miner Res. 2005 Nov;20(11):1905-11 PubMed
J Bone Miner Res. 2003 Jan;18(1):9-17 PubMed
Bone. 2010 Jun;46(6):1486-97 PubMed
Eur J Endocrinol. 2011 Apr;164(4):643-8 PubMed
Rev Endocr Metab Disord. 2006 Jun;7(1-2):113-21 PubMed
J Clin Endocrinol Metab. 1994 Sep;79(3):730-5 PubMed
J Biol Chem. 2010 Sep 3;285(36):28164-73 PubMed
J Clin Endocrinol Metab. 2005 Aug;90(8):4644-9 PubMed
J Bone Miner Res. 2007 Aug;22(8):1173-80 PubMed
Endocrinology. 2002 Oct;143(10):4038-47 PubMed
J Bone Miner Res. 1991 Jul;6(7):759-66 PubMed
J Bone Miner Res. 2003 Nov;18(11):1932-41 PubMed
J Bone Miner Res. 2006 Mar;21(3):366-73 PubMed
Bone. 2007 Jun;40(6):1434-46 PubMed
Bone. 2002 Jul;31(1):57-61 PubMed
J Bone Miner Res. 2008 Oct;23(10):1591-600 PubMed
